Pomerantz LLP is investigating claims on behalf of investors of HCA Healthcare, Inc. The investigation concerns whether HCA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On July 14, 2026, HCA sharply lowered its full-2026 profit guidance, citing an unfavorable shift in payer mix that impacted revenue by approximately $400 million in the second quarter. Following that news, HCA’s stock price fell $27.14 per share, or 6.95%, to close at $363.60 per share on July 14, 2026. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
HCA Healthcare, Inc.HCA lowered its 2026 profit guidance due to unfavorable payer mix, causing a 6.95% stock drop and triggering a securities fraud investigation.
